Celldex Therapeutics, Inc. (NASDAQ:CLDX) Releases Earnings Results, Beats Expectations By $0.05 EPS

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05, Bloomberg Earnings reports. Celldex Therapeutics had a negative net margin of 1,825.82% and a negative return on equity of 53.10%. The business had revenue of $3.83 million during the quarter, compared to analyst estimates of $1.21 million. During the same quarter last year, the business posted ($0.32) earnings per share. Celldex Therapeutics’s revenue for the quarter was up 175.5% compared to the same quarter last year.

Celldex Therapeutics (CLDX) traded down 1.17% during midday trading on Wednesday, reaching $2.53. 2,455,371 shares of the company traded hands. The stock’s market capitalization is $316.51 million. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $5.02. The company has a 50 day moving average of $2.46 and a 200-day moving average of $3.04.

A number of analysts have commented on CLDX shares. Jefferies Group LLC reaffirmed a “hold” rating and set a $3.50 target price (down previously from $4.00) on shares of Celldex Therapeutics in a report on Thursday, May 11th. Zacks Investment Research raised shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a report on Wednesday, May 31st. ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 3rd. Cowen and Company reaffirmed a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, June 6th. Finally, Aegis reaffirmed a “buy” rating on shares of Celldex Therapeutics in a report on Thursday, June 29th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Celldex Therapeutics has an average rating of “Hold” and a consensus target price of $7.32.

ILLEGAL ACTIVITY NOTICE: “Celldex Therapeutics, Inc. (NASDAQ:CLDX) Releases Earnings Results, Beats Expectations By $0.05 EPS” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/2796027/celldex-therapeutics-inc-nasdaqcldx-releases-earnings-results-beats-expectations-by-0-05-eps.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Earnings History for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.